Clinical Trials
2 trialsNCT06802146 2026-04-23
Early Intervention in High Risk CCUS
Dana-Farber Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT06284460 2026-02-13
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn